SL
Silence Therapeutics plc
SLNCF · OTC
$4.40 +10.00% (+$0.40)
1M -11.11%
Market Cap $623.5M
P/E Ratio -
Div. Yield -
ROE 106.94%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 1,013.82x
P/B 16.21x
P/E N/A
Growth
22 /100
Declining Rev. growth 68.27%
Book val. growth 41.33%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 13.82%
FCF margin 6,334.92%
Net margin 9,748.46%
Quality
0 /100
Poor ROIC 61.89%
Asset turnover 0.01x
ROE 106.94%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 7.42x
Int. coverage N/A
Stability
17 /100
Unstable Beta 1.41x
Profitable years 0
Rev. volatility 91.22%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SLNCF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London